GAMMA Investing LLC Buys New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

GAMMA Investing LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 104 shares of the company’s stock, valued at approximately $30,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Medpace by 2.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock valued at $2,114,000 after acquiring an additional 148 shares in the last quarter. Portside Wealth Group LLC grew its stake in shares of Medpace by 14.8% in the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock valued at $435,000 after purchasing an additional 183 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Medpace by 355.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after buying an additional 2,774 shares in the last quarter. Louisiana State Employees Retirement System bought a new position in shares of Medpace during the 4th quarter worth approximately $1,992,000. Finally, Chase Investment Counsel Corp boosted its stake in Medpace by 3.2% in the 3rd quarter. Chase Investment Counsel Corp now owns 9,849 shares of the company’s stock valued at $2,384,000 after buying an additional 301 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.4 %

Shares of MEDP stock opened at $392.57 on Monday. The firm has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.95 and a beta of 1.40. Medpace Holdings, Inc. has a 12 month low of $197.39 and a 12 month high of $421.00. The stock has a 50-day moving average price of $398.08 and a 200 day moving average price of $331.78.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same quarter last year, the firm earned $2.27 EPS. The company’s revenue for the quarter was up 17.7% on a year-over-year basis. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Guggenheim lifted their price target on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and boosted their price target for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Robert W. Baird raised their price objective on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $443.00.

Insider Buying and Selling at Medpace

In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 204,442 shares of company stock worth $82,702,867. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.